Vorasidenib

Servier presented the latest clinical data on the IDH1/2 inhibitor vorasidenib (AG-881) in the treatment of IDH-mutated diffuse glioma at the 28th Annual Meeting of the Society of Neuro-Oncology (SNO). Blinded independent radiology committee evaluation showed that vorasidenib significantly reduced tumor growth and not only preserved the patient's quality of life, but also stabilized neurocognitive function and controlled epilepsy. Based on these results, the company plans to submit a new drug application for vorasidenib to the U.S. FDA by the end of 2023 for the treatment of IDH-mutated diffuse glioma. Vorasidenib is an oral, brain-penetrating and selective dual inhibitor under development that can inhibit mutated IDH1/2 proteins and is a potential "first-in-class" drug. It has received breakthrough therapy designation from the FDA.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.